In clinical oncology and drug development there is genuine need for sensitive and reproducible quantitative imaging methods for early prediction of therapy response and accurate assessment of post-therapy residual cancer. Such methods have the potential to spare non-responding patients from ineffective and/or toxic treatments, improve clinical management, and accelerate efficacy evaluation of novel therapies. Dynamic- Contrast-Enhanced (DOE) MRI can provide an excellent measure of therapy-induced tumor vascular changes. The Standard-Model (SM) for pharmacokinetic DCE-MRl analysis incorrectly assumes effectively infinitely fast equilibrium inter-compartmental water exchange kinetics and, as a result, often underestimates the pharmacokinetic parameters Ktrans and Ve. The Shutter-Speed Model (SSM) accounts for finite water exchange kinetics effects and corrects the imaging biomarker underestimations. It has proven more sensitive to vascular changes than the SM. In addition, SSM DCE-MRl allows quantification of novel imaging biomarkers, such as ?Ktrans(= Ktrans (SSM) - Ktrans (SM)] - a measure of precisely the water exchange (shutter-speed) effect on Ktrans estimation. ?Ktransis not only a more sensitive biomarker for therapeutic response, but also less prone to other systematic errors often observed in DCE-MRl quantification.
In Specific Aim 1, the Shutter-Speed Model will be applied to phase l/ll clinical trials in two disease areas (breast cancer and soft tissue sarcoma), SSM DCE-MRl will be compared/combined with SM DCE-MRl, diffusion-weighted MRI and tumor size measurement for assessment of therapy response.
In Aim 2, the effects of data acquisition and processing schemes on DCE-MRl biomarker values will be investigated within the context of therapeutic monitoring.
In Aims 1 and 2, pathology results will be used as endpoints for correlation with imaging results and statistical analyses.
In Aim 3, caBIG-compliant software tools will be developed that utilize a single and/or a set of imaging biomarkers to aid clinical research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA154602-03
Application #
8533769
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (M1))
Program Officer
Nordstrom, Robert J
Project Start
2011-09-01
Project End
2016-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
3
Fiscal Year
2013
Total Cost
$542,095
Indirect Cost
$190,085
Name
Oregon Health and Science University
Department
None
Type
Organized Research Units
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Springer Jr, Charles S; Li, Xin; Tudorica, Luminita A et al. (2014) Intratumor mapping of intracellular water lifetime: metabolic images of breast cancer? NMR Biomed 27:760-73
Huang, Wei; Li, Xin; Chen, Yiyi et al. (2014) Variations of dynamic contrast-enhanced magnetic resonance imaging in evaluation of breast cancer therapy response: a multicenter data analysis challenge. Transl Oncol 7:153-66
Kalpathy-Cramer, Jayashree; Gerstner, Elizabeth R; Emblem, Kyrre E et al. (2014) Advanced magnetic resonance imaging of the physical processes in human glioblastoma. Cancer Res 74:4622-37
Li, Xin; Priest, Ryan A; Woodward, William J et al. (2013) Feasibility of shutter-speed DCE-MRI for improved prostate cancer detection. Magn Reson Med 69:171-8
Meyer, Janelle M; Perlewitz, Kelly S; Hayden, James B et al. (2013) Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res 19:6902-11